David Stenehjem, PharmD, BCOP

Real-World Data of Immunotherapy in Non-Small Cell Lung Cancer: Evidence for a Precision Medicine Approach?


October 2, 2020 | 2:00 to 3:00 p.m. CT | presented online via Zoom

David Stenehjem, PharmD, BCOP is an Associate Professor and Associate Department Head in the Department of Pharmacy Practice and Pharmaceutical Sciences at the University of Minnesota, College of Pharmacy. He is a member of the Masonic Cancer Center at the University of Minnesota, a Comprehensive Cancer Center designated by the National Cancer Institute. Dr. Stenehjem's outcomes-based research agenda is centered around assessing the role and value of oncology therapeutics and precision oncology in improving outcomes for cancer patients. His research strategy uses real world data collected from major cancer centers across the nation to assess clinical and economic outcomes of cancer patients treated with specific therapeutic agents. This approach allows for the molecular stratification of patients while assessing meaningful outcomes to demonstrate the value of precision oncology and specific cancer treatments. Additionally, translational research is supported by assessing the implications of novel biomarkers with treatment response. He is also a co-director of a pharmacogenomic implementation fellowship program in partnership with Essentia Health in Duluth.

The webinar is offered to attendees at no cost. We hope you’ll join us!


Join the seminar via Zoom:  z.umn.edu/pmseminar

(The above link will redirect to the live seminar on Zoom approximately 10 minutes before the start time)

David Stenehjem